Clinical trial NCT06770569: Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Official title: Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors: a Single-arm, Open, Multicenter Phase I Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumors
Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-01-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is being conducted to evaluate the safety and tolerability of HRS-3802 monotherapy in patients with advanced solid tumors


Eligibility criteria: Inclusion Criteria:

1. Patients must be willing to participate in the study, sign the informed consent form, have good compliance, and cooperate with follow-up visits.
2. Age ≥18 years, male or female
3. Patients with advanced malignant tumors confirmed pathologically;
4. Failure of adequate standard treatment, or no effective standard treatment;
5. Patients must have at least 1 extracranial measurable target lesion per RECIST v1.1 ;
6. The expected survival period is more than 12 weeks;
7. The Eastern Cooperative Oncology Group (ECOG) physical fitness score is 0 - 1;
8. Have sufficient bone marrow and organ function (have not received blood transfusion or hematopoietic stimulating factor treatment within 14 days):
9. Female subjects of childbearing age must undergo a serum pregnancy test within 7 days before starting the study medication, and the result is negative, and are willing to use a medically approved high-efficiency contraception during the study period and within 1 months after the last administration of the study drug Measures:

Exclusion Criteria:

1. Subjects had cancerous meningitis or untreated central nervous system metastases
2. Subjects had severe cardiovascular and cerebrovascular diseases
3. There is third-space effusion that cannot be controlled by drainage and other methods (such as massive ascites, pleural effusion, pericardial effusion)；
4. Subjects had or currently had idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia , drug pneumonia, or CT during screening showed active pneumonia；
5. Arteriovenous thrombosis occurred within 6 months prior to the first dose
6. Severe infection occurred within 4 weeks prior to initial administration
7. Subjects with refractory nausea, vomiting, or other gastrointestinal disorders that affect the use of oral medications: including malabsorption syndrome
8. Known history of human immunodeficiency virus (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS)
9. Subjects had active hepatitis；
10. Subjects were scheduled to receive other systemic antitumor therapies during the study period；
11. Known allergies and contraindications to the investigational drug or any of its components；
12. Other factors as judged by the investigator that may lead to the termination of the study, such as other serious diseases, serious laboratory test abnormalities, or family or social factors that could affect the safety of the subject, or the collection of study data and samples.

Primary outcomes:
measure: Number of subjects with adverse events and the severity of adverse events
timeFrame: every 4 weeks after treatment initiation（through study completion，an average 5mouthes）
measure: DLT(Dose-limiting toxicity）
timeFrame: during the first 28-day cycle of HRS-3802 treatment
measure: MTD（Maximum tolerated dose）
timeFrame: 3 weeks after treatment initiation
measure: RP2D（Recommended Phase II Dose）
timeFrame: 3 weeks after treatment initiation
Secondary outcomes:
measure: ORR（Objective response rate (ORR) - RECIST 1.1
timeFrame: Up to approximately 6 months
measure: DoR（Duration of Response (DoR)Duration of Response (DoR) per RECIST 1.1）
timeFrame: Up to approximately 2 years
measure: PFS-Progression-free survival(PFS) PFS per RECIST 1.1
timeFrame: Up to approximately 2 years]
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Hospital Chinese Academy of Medical Sciences
state: Beijing
Study officials:
References: